RiaSTAP

In patients with fibrinogen deficiency, now along with cryopreciptate Fibrinogen Concentrate (Human) - Trade name RiaSTEp is available. RiaSTAP is not indicated for dysfibrinogenemia, but is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. It may be use in acute post-op bleeding due to hypofibrinogenemia. Dose should be individually calculated for each patient based on

•  the target plasma fibrinogen level
• actual measured plasma fibrinogen level and
• body weight

formula is 

[Target level (mg/dL) - measured level (mg/dL)] /
 1.7 (mg/dL per mg/kg body weight)

When baseline fibrinogen level is not known, the recommended dose is 70 mg per kg of body weight.

Reference:

RiaSTEP package http://www.fda.gov/downloads/Biolog...ionatedPlasmaProducts/ucm094006.pdf